Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by equities research analysts at Goldman Sachs Group from a “buy” rating to a “conviction-buy” rating in a research report issued on Friday, The Fly reports.
ALNY has been the topic of several other reports. Credit Suisse Group boosted their target price on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an “outperform” rating in a research note on Friday, November 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 price target (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $14.71 price target (down previously from $188.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 2nd. B. Riley began coverage on Alnylam Pharmaceuticals in a research report on Wednesday, November 1st. They set a “buy” rating and a $240.00 price target for the company. Finally, Nomura began coverage on Alnylam Pharmaceuticals in a research report on Thursday, September 14th. They set a “reduce” rating and a $56.00 price target for the company. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $121.85.
Alnylam Pharmaceuticals (ALNY) opened at $123.66 on Friday. Alnylam Pharmaceuticals has a one year low of $35.98 and a one year high of $147.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.
In other news, EVP Akshay Vaishnaw sold 33,666 shares of the business’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $121.46, for a total value of $4,089,072.36. Following the completion of the transaction, the executive vice president now owns 45,201 shares of the company’s stock, valued at approximately $5,490,113.46. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO John Maraganore sold 74,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total value of $9,387,640.00. Following the completion of the transaction, the chief executive officer now directly owns 223,710 shares of the company’s stock, valued at approximately $28,379,850.60. The disclosure for this sale can be found here. In the last three months, insiders sold 393,212 shares of company stock valued at $48,109,436. Insiders own 4.30% of the company’s stock.
Several institutional investors have recently made changes to their positions in ALNY. Jennison Associates increased its stake in shares of Alnylam Pharmaceuticals by 55.4% in the 3rd quarter. Jennison Associates now owns 1,482,245 shares of the biopharmaceutical company’s stock valued at $119,113,000 after purchasing an additional 528,598 shares in the last quarter. TrimTabs Asset Management purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $1,770,000. Taylor Wealth Management Partners increased its stake in shares of Alnylam Pharmaceuticals by 0.3% in the 4th quarter. Taylor Wealth Management Partners now owns 31,205 shares of the biopharmaceutical company’s stock valued at $2,938,000 after purchasing an additional 85 shares in the last quarter. Reynolds Capital Management purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $264,000. Finally, Fourth Swedish National Pension Fund increased its stake in shares of Alnylam Pharmaceuticals by 2.6% in the 4th quarter. Fourth Swedish National Pension Fund now owns 21,581 shares of the biopharmaceutical company’s stock valued at $2,032,000 after purchasing an additional 544 shares in the last quarter. Hedge funds and other institutional investors own 88.43% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking and Market News and is the property of of American Banking and Market News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/15/alnylam-pharmaceuticals-alny-upgraded-by-goldman-sachs-group-to-conviction-buy.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
